LogixX Pharma is managed by pharmaceutical entrepeneurs with experience in developing and commercialising therapeutic options for patients needs.
With experience spanning commercialisation of research and development projects, they deploy their expertise in late-phase clinical trials, registration and approval processes, and in market access activities across different markets.
Michael Close, CEO and founder
Since founding the Company and becoming CEO in 2010, Michael has focused on leveraging the uniqueness of LogixX Pharma in serving its clients with an emphasis on strong execution and the highest ethical and regulatory standards primarily in the metabolic and paediatric markets. Today LogixX Pharma generates a significant proportion of its growth in male and female fertility and sexual health products.
Overseeing the development of licensing and partnerships, the identification and initiation of new projects, and the business unit’s entire portfolio, Michael has a vision to support the patient communities, health care professionals and employees in growing the company’s portfolio through innovation, lifecycle management and geographical expansion. He has a strong track record in commercialising novel therapeutics to market by developing successful partnerships, applying expertise in commercial and regulatory activities, registration and approval, and advancing market access.
Since 2010, Michael has led the company’s activities in partnering with other companies without a presence in the UK market. He partnered several Italian, German and US based start-up companies in providing a Commercial and Regulatory foundation in which to grow. He supported Pharmaceutical product transfers back to the originating company to further commercialise the assets at Group level in the area of oncology and rare/orphan diseases. He took ownership of sigma-tau's UK traditional and health science business in October 2013.
Michael has extensive experience in commercialisation, logistics and development of medicines and medical devices in several therapeutic areas. Michael Close is also the MHRA approved Responsible Person of LogixX Pharma Solutions Ltd, and also serves on the board of Shard Speciality Pharma Ltd. Prior to LogixX Pharma, Michael held a number of senior posts with Merck Serono Ltd, and previously with Solvay and Bayer. He holds a degree in Biomedical Science from the University of Wolverhampton.